Lanean...
Trimetazidine Use in Parkinson’s Disease: Is It a Resolved Problem?
Trimetazidine (TMZ), an antianginal drug, can worsen the symptoms of movement disorders, therefore, the European Medicines Agency (EMA) recommended avoiding the use of this drug in Parkinson’s disease (PD). We investigated the impact of this recommendation on the observed trend of TMZ use in PD in H...
Gorde:
| Argitaratua izan da: | eNeuro |
|---|---|
| Egile Nagusiak: | , , , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Society for Neuroscience
2021
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8143021/ https://ncbi.nlm.nih.gov/pubmed/33863783 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1523/ENEURO.0452-20.2021 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|